Lusaris Therapeutics Funding: $60M Raised, Series A (2022)
Lusaris Therapeutics is based in Boston. It has raised $60M in total funding. Latest round: Series A. Backed by RA Capital Management, OrbiMed, Boxer Capital.
Lusaris Therapeutics funding overview
Lusaris Therapeutics is based in Boston. Lusaris Therapeutics has raised $60M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series A announced in November 2022. The round record for Lusaris Therapeutics runs through 2022; nothing later has been disclosed. Investors on record include RA Capital Management, OrbiMed, Boxer Capital, Deep Track Capital, Venrock. 5 distinct backers are named across the disclosed rounds.
Lusaris Therapeutics at a glance
Total raised
$60M
Latest round
Series A
Latest round date
November 2022
Headquarters
Boston
Notable investors
RA Capital Management, OrbiMed, Boxer Capital, Deep Track Capital, Venrock
Frequently asked about Lusaris Therapeutics funding
How much has Lusaris Therapeutics raised?
Lusaris Therapeutics has raised $60M in total disclosed funding across the rounds on record.
Who has invested in Lusaris Therapeutics?
RA Capital Management, OrbiMed, Boxer Capital, Deep Track Capital, Venrock are named among the investors backing Lusaris Therapeutics.
What was the latest Lusaris Therapeutics funding round?
The most recent disclosed round is a Series A, announced in November 2022.
Where is Lusaris Therapeutics based?
Lusaris Therapeutics is based in Boston.
When did Lusaris Therapeutics last raise?
The last disclosed Lusaris Therapeutics round closed in November 2022 at Series A.
Lusaris Therapeutics totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related companies in Boston below to benchmark round size and investor mix.
